National Institutes of Health Update

Claire Schuster, MPH National Institute of Allergy and Infectious Diseases National Institutes of Health

September 2021





FluMos-v1: Universal Influenza Vaccine Candidate



A computer-generated image showing HA epitopes arrayed on a nanoparticle *Credit: NIAID*

- NIH launches Phase 1 Clinical Trial of FluMos-v1
 - FluMos-v1 is an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains that was developed by NIAID scientists and collaborators at the University of Washington
 - Purpose: To assess the safety and immunogenicity of FluMos-v1
 - Participants: Up to 35 participants between 18 and 50 years old
 - Location: NIH Clinical Center, Bethesda, MD



Researching COVID to Enhance Recovery (RECOVER)



Long-term effects of COVID are real. Join

the search for answers.

Have questions about the long-term health effects of the virus? Start by learning about PASC.

SHARE TO RAISE AWARENESS





ABOUT

FAQS

RESOURCES

LATEST UPDATES

Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

- Notice of Special Interest (NOSI)
 - Purpose: To solicit community-engaged research to:
 - 1) Evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and
 - 2) Address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.
 - Awards: For example, National Institute on Minority Health and Health Disparities (NIHMD) recently awarded 5 research grants totaling \$14.5 million over 5 years for these grants, subject to available funds.

https://nimhd.nih.gov/news-events/news-releases/2021/pr-2021-06-04vaccine-hesitancy-research.html





National Institute of Allergy and Infectious Diseases (NIAID) http://www.niaid.nih.gov June 1, 2021

NIH Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins



Credit: NIH






National Institute of Allergy and Infectious Diseases (NIAID) http://www.niaid.nih.gov August 10, 2021

NIH Launches Study of Third COVID-19 Vaccine Dose in Kidney Transplant Recipients

Trial Will Assess Antibody Response in People Who Did Not Respond to Two-Dose Regimen



Credit: NIAID



SNIFF Study

av 03 2021 at 8-51 AM ED

- Novavax is conducting a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19.
 - Enrolling up to 3,000 adolescents aged 12-17 across up to 75 sites, including 8 COVID-19 Prevention Network (CoVPN) sites.
- Ancillary nasal swab study called SNIFF (Swab your Nose to Find inFection) to assess asymptomatic viral shedding of SARS-CoV-2.







National Institute of Allergy and Infectious Diseases (NIAID) http://www.niaid.nih.gov June 23, 2021

NIH Begins Study of COVID-19 Vaccination During Pregnancy and Postpartum

Researchers Will Evaluate Antibody Responses in Vaccinated Participants and Their Infants



Credit: NIAID

